Relationship between plasma phospholipid polyunsaturated fatty acid composition and bone disease in renal transplantation.
To investigate the relationship between polyunsaturated fatty acid (PUFA) and bone metabolism in renal transplant patients, plasma phospholipid (PP) PUFA levels, biochemical markers of bone turnover and bone mineral density (BMD) were determined in 22 recipients of a first renal allograft at baseline and after a mean 24.4 month follow-up. A significant increase in PP n-3 PUFA content, in the [n-3 PUFA/ arachidonic acid] ratio and in BMD values was observed, as well as a close correlation between the increase in PP n-3 PUFA content and femoral neck BMD. Multivariate regression analysis showed that BMD improvement was positively related to PP n-3 PUFA variation and baseline PP eicosapentaenoic acid levels, and negatively to PP arachidonic acid modification. Tacrolimus- versus cyclosporine-treated patients demonstrated a significant increase in femoral neck BMD and PP n-3 PUFA content. This is the first longitudinal study showing a link between PP-PUFA composition and bone disease in renal transplantation.
Baggio
Bruno
B
Department of Medical and Surgical Sciences, University of Padova, and Central Laboratory, University Hospital of Padova, Italy. bruno.baggio@unipd.it
Budakovic
Alessandro
A
Ferraro
Alberto
A
Checchetto
Simone
S
Priante
Giovanna
G
Musacchio
Estella
E
Manzato
Enzo
E
Zaninotto
Martina
M
Maresca
Maria-Cristina
MC
D000328:Adult; D016718:Arachidonic Acid / Q000097:blood; D015415:Biomarkers / Q000097:blood; D015519:Bone Density; D001847:Bone Diseases / Q000209:etiology*; D016723:Bone Remodeling; D016572:Cyclosporine / Q000627:therapeutic use; D015525:Fatty Acids, Omega-3 / Q000097:blood; D005231:Fatty Acids, Unsaturated / Q000097:blood*; D005260:Female; D005272:Femur Neck / Q000378:metabolism; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000009:adverse effects*; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D010743:Phospholipids / Q000097:blood*; D016559:Tacrolimus / Q000627:therapeutic use
D015415:Biomarkers; D015525:Fatty Acids, Omega-3; D005231:Fatty Acids, Unsaturated; D007166:Immunosuppressive Agents; D010743:Phospholipids; D016718:Arachidonic Acid; D016572:Cyclosporine; D016559:Tacrolimus